tive intermediates that oxidize lipoproteins in vitro. To explore the potential role of myeloperoxidase in the development of atherosclerosis, we determined whether the enzyme was present in surgically excised human vascular tissue. In detergent extracts of atherosclerotic arteries subjected to Western blotting, a rabbit polyclonal antibody monospecific for myeloperoxidase detected a 56-kD protein, the predicted molecular mass of the heavy subunit. Both the immunoreactive protein and authentic myeloperoxidase bound to a lectin-affinity column; after elution with methyl mannoside their apparent molecular masses were indistinguishable by nondenaturing size-exclusion chromatography. Peroxidase activity in detergent extracts of atherosclerotic lesions likewise bound to a lectin column and eluted with methyl mannoside. Moreover, eluted peroxidase generated the cytotoxic oxidant hypochlorous acid (HOCI), indicating that enzymatically active myeloperoxidase was present in lesions. Patterns of immunostaining of arterial tissue with antihuman myeloperoxidase antibodies were similar to those produced by an antimacrophage antibody, and were especially prominent in the shoulder region of transitional lesions. Intense foci of myeloperoxidase immunostaining also appeared adjacent to (1) . A potential mechanism is the unregulated uptake of modified forms of low density lipoprotein (LDL) by the scavenger receptor (2, 3) . This receptor recognizes LDL modified by products of lipid peroxidation (4) (5) (6) (7) , raising the possibility that oxidation makes LDL atherogenic. Oxidized LDL has other possible atherogenic effects in vitro, including stimulation of monocyte recruitment (8) and adhesion to endothelium (9) , promotion of intramural thrombosis (10) , activation of lymphocytes (11) , and cytotoxicity ( 12) .
The hypothesis that LDL oxidation is involved in the pathogenesis of atherosclerosis is strongly supported by several lines of evidence. Proteins altered by peroxidized lipids colocalize in part with the apolipoprotein B100 of LDL in rabbit atherosclerotic lesions (13) (14) (15) . Lipoprotein-like particles with properties consistent with oxidative damage have been isolated from animal and human aortic lesions (16, 17) ; these particles promote cholesterol accumulation by macrophages (16, 17) . Finally, chemically unrelated antioxidants retard lesion formation in hypercholesterolemic rabbits (18) (19) (20) (21) (22) , indicating that oxidized lipoproteins may play a causal role in atherosclerosis.
The mechanisms that oxidatively damage lipoproteins in vivo remain poorly understood. Cultured endothelial cells (3, 5, 12) , smooth muscle cells (6, 12) , and monocyte-derived macrophages (23, 24) modify LDL by reactions that require iron or copper (6) , implicating cellular mechanisms and free metal ions in lipoprotein oxidation. Studies with pharmacologic inhibitors suggest that 15-lipoxygenase mediates LDL oxidation by mouse peritoneal macrophages and a transformed rabbit endothelial cell line (25, 26) . However, most lipoxygenase inhibitors are potent antioxidants (27, 28) , making interpretation of the results difficult. Moreover, the extent of LDL lipid peroxidation by cultured cells fails to correlate with endogenous lipoxygenase activity (27) . Although macrophage-associated 15-lipoxygenase has been detected in atherosclerotic lesions (29) , its role in lipoprotein oxidation is not understood. Cultured human arterial smooth muscle cells (30) and rabbit endothelial cells (31 ) produce extracellular superoxide (°2-), and oxidize LDL by an°2-mediated reaction that requires metal ions (6, 30) . Both O2-generation and LDL modification are L-cystinedependent processes (32) , suggesting that cellular generation of thiol is involved (32, 33) . The biological relevance of these pathways has not been established.
Activated monocytes oxidatively modify LDL in vitro by a mechanism that is inhibited by superoxide dismutase, catalase, by a membrane-associated NADPH oxidase (35) . Activated monocytes also secrete a heme enzyme, myeloperoxidase, that uses H202 as a substrate to generate products that can oxidize lipids (36) (37) (38) and proteins (39) (40) (41) . One product is hypochlorous acid (HOCI),' which is formed from CP (42) . This potent cytotoxin plays a critical role in host defenses against invading bacteria, viruses, and tumor cells, but it may also injure normal tissue (43) (44) (45) . Another product of the myeloperoxidase-H202 system at plasma concentrations of Cl -and amino acids is tyrosyl radical (46) overnight with 0.5 ml concanavalin A gel (Sigma Chemical Company, St. Louis, MO) with intermittent inversion at 40C. The gel was pelleted by centrifugation and resuspended in wash buffer (0.1 M sodium acetate, 0.1 M NaCl, 0.05% CTAB, pH 6.0). After two washes with 10 ml wash buffer at 40C, the gel was poured into a minicolumn (0.4 cm2 x 1.3 cm), washed three times with 1 ml wash buffer at room temperature, and centrifuged for 5 min at 1,000 g to remove residual wash buffer. Material bound to the lectin gel was eluted three times by incubation with 0.3 ml elution buffer (0.5 M methyl a-D-mannoside in wash buffer) for 10 min at room temperature. Fractions were pooled with elution buffer recovered by centrifugation of the minicolumn and stored at 40C until analysis. Protein concentration was determined as described by Lowry et al. (55) with the use of bovine serum albumin as the standard.
Peroxidase activity in detergent extracts prepared from atherosclerotic and normal arteries was monitored by the guaiacol oxidation method of Klebanoff et al. (56) heavy myeloperoxidase subunit (Fig. 1 A) .. When the dye front was retained on the gel, an immunoreactive protein was observed that comigrated with the light subunit of myeloperoxidase. Purified myeloperoxidase, isolated by lectin affinity chromatography and gel filtration chromatography from the neutrophils of a patient with chronic myelogenous leukemia, comigrated with the immunoreactive material (Fig. 1 A) . When large amounts of myeloperoxidase were subjected to electrophoresis, a minor band of 34 kD was sometimes detectable (Fig. 1 B) . This component, which has been reported by many different investigators, is an autolytic product of the enzyme (59) . Thus, the rabbit antibody was monospecific for myeloperoxidase. The rabbit polyclonal antibody was used to determine whether myeloperoxidase was present in detergent extracts of human vascular lesions. Tissue was excised from atherosclerotic abdominal aortic aneurysms, occlusive abdominal aortic and femoral atherosclerotic lesions, and carotid endarterectomy specimens. After detergent-soluble proteins were subjected to SDS-PAGE, immunoblotting with the rabbit antibody revealed an immunoreactive protein of 56 kD that comigrated with authentic myeloperoxidase (Fig. 1 B) . The subtle differences in apparent molecular mass of the immunoreactive protein may reflect the presence of myeloperoxidase isozymes (60) (61) (62) . All 14 atherosclerotic arteries examined by Western blotting contained immunoreactive myeloperoxidase.
Human myeloperoxidase is a glycoprotein that binds tightly to lectins (54) . The immunoreactive material in detergent extracts of atherosclerotic arteries bound to a concanavalin A column and eluted with methyl a-D-mannoside, as did authentic myeloperoxidase. When the protein isolated from the lectin column was subjected to high-resolution nondenaturing size exclusion chromatography on a Superose-12 H/R column, the apparent sizes (68 kD) of the immunoreactive material and myeloperoxidase were identical (Fig. 2) . The anomalous apparent molecular mass of myeloperoxidase on gel filtration chromatography, which has been reported for both the canine (63) and human enzyme (64) , reflects in part its highly asymmetrical shape (64) . The results of lectin and size exclusion chromatography, together with those from Western blotting, provides strong evidence that human atherosclerotic tissue contains myeloperoxidase.
To determine whether the myeloperoxidase in atherosclerotic tissue was enzymatically active, detergent extracts prepared from surgically excised atherosclerotic and grossly normal arteries were tested for peroxidase activity with guaiacol as the reducing substrate (56) . Peroxidase activity was readily detected in six out of nine atherosclerotic lesions (mean activity, 251 guaiacol U/mg protein; range, 71-511), but was absent from three normal arteries. The peroxidase activity in detergent extracts prepared from atherosclerotic arteries bound to a concanavalin A column and was eluted with methyl a-D-mannoside. Moreover, the peroxidase isolated from the concanavalin A column generated HOC1 as assessed by the oxidation of monochlorodimedone (Fig. 3) . As expected for myeloperoxidase, the reaction was chloride dependent. Eosinophil peroxidase is the only other human enzyme known to generate HOC1 (65), but eosinophils are not thought to be involved in atherosclerosis (1) . These results strongly suggest that enzymatically active myeloperoxidase is expressed in human vascular lesions.
To localize myeloperoxidase in vascular lesions, surgically excised and rapidly frozen sections of atherosclerotic tissue were probed with a mouse monoclonal antibody to myeloperoxidase. The monoclonal antibody demonstrated considerable immunoreactivity in the shoulder region of transitional lesions (Fig. 4 A) . There was negligible immunostaining for myeloperoxidase in normal intima and media (Fig. 4 B) . Immunoreactivity for myeloperoxidase was also noted in the adventitia, as has been reported for multiple antibodies that react with oxidized LDL ( 13-15, 66 ). There was intense perinuclear immunoreactivity in macrophage-rich regions of transitional lesions, indicating that myeloperoxidase was present intracellularly. The distorted morphology that is characteristic of advanced atherosclerotic lesions made it difficult to visualize cellular boundaries by light microscopy. Thus, it was difficult to show unequivocally that myeloperoxidase was present extracellularly. However, myeloperoxidase immunostaining was widespread in many such regions, consistent with both an intra-and extracellular distribution of the enzyme.
A mouse monoclonal antibody that recognizes CD68, an epitope specific for monocytes and macrophages (67, 68) , was used to locate this cell type in human lesions. The pattern of immunostaining for macrophages in sections of transitional lesions (Fig. 5 B) resembled the distribution of immunostaining for myeloperoxidase with the mouse monoclonal antibody (Fig.  5 A) Elution Volume (ml) sel wall. However, immunostaining was negligible for neutrophil elastase in atherosclerotic lesions (Fig. 5 C) . In contrast, bone marrow neutrophils exhibited markedly positive immunostaining with this antibody. Regions containing large numbers of cells that reacted with HHF-35, a mouse monoclonal antibody which recognizes smooth muscle cell actins (53) , immunostained poorly with the myeloperoxidase antibody (data not shown). There was neglible deposition of chromogen when the primary antibody was excluded from the avidin-biotin-peroxidase detection system (Fig. 5 D) .
, , Figure 3 . 25 Western blotting with the rabbit polyclonal antibody to myeloperoxidase.
Sections of tissue prepared on a cryostat were incubated with H202 and 3-amino-9-ethylcarbazole, a nonspecific peroxidase substrate, to determine endogenous peroxidase activity. The localization of red chromogen within atherosclerotic lesions was similar to that observed with the rabbit antibody and mouse monoclonal antibody to myeloperoxidase, although staining was generally much less intense than for immunostained myeloperoxidase. The diminished intensity of endogenous peroxidase staining may reflect damage to the activity of myeloperoxidase during its prolonged residence in the artery wall. In addition, immunochemical localization of myeloperoxidase with biotinylated reagents amplifies the peroxidase reaction.
To document further the presence of myeloperoxidase in atherosclerotic lesions, paraffin-embedded tissue sections prepared from paraformaldehyde-fixed lesions were immunostained with the rabbit polyclonal antibody. Surgically excised tissue samples from abdominal aortic aneurysms, atherosclerotic aortic lesions, and occluded femoral arteries and tissue obtained at carotid endarterectomy were examined; each of the 31 samples exhibited considerable immunoreactivity within lesions. Immunostaining was most marked in the acellular lipidrich necrotic core of complicated lesions (Fig. 6 A) . The distribution of immunostaining in advanced lesions was striking, with dense foci of material localized adjacent to cholesterol clefts (Fig. 6 A) . Immunoreactivity with the polyclonal antibody to myeloperoxidase was blocked by preincubating the rabbit polyclonal antibody with myeloperoxidase (Fig. 6 B) Figure 4 . Atherosclerotic lesions, but not normal intima or media, exhibit immunoreactive myeloperoxidase. Fresh frozen sections prepared from a surgically excised human abdominal aorta (A) and normal abdominal aorta obtained from a young organ donor (B) were subjected to immunocytochemical analysis with a mouse monoclonal antibody to human myeloperoxidase (1:50 dilution). Primary antibody was detected as red 3-amino-9-ethylcarbazole reaction product with a avidin-biotin--peroxidase system as described in Methods. Tissue sections were counterstained with hematoxylin. M and I indicate the medial and intimal regions, respectively, and the bar corresponds to 0.5 mm.
kD protein that was immunoreactive with the rabbit polyclonal antibody monospecific for myeloperoxidase was present in detergent extracts of atherosclerotic arteries. The apparent molecular masses of the immunoreactive protein and myeloperoxidase were indistinguishable by Western blotting. Second, immunoreactive material extracted from atherosclerotic arteries bound to a concanavalin A column. After elution with methyl a-Dmannoside, the reisolated protein and myeloperoxidase demonstrated the same apparent molecular mass on high-resolution nondenaturing size exclusion chromatography. Moreover, the reisolated protein generated HOCI, an oxidizing product of myeloperoxidase activity. Third, the monospecific polyclonal rabbit antibody and the mouse monoclonal antibody to human myeloperoxidase immunostained macrophage-rich shoulder regions of transitional lesions. Collectively, these results identify the oxidative heme enzyme, myeloperoxidase, as a component of human atherosclerotic lesions.
The distribution of immunolocalized myeloperoxidase varied in different types of atherosclerotic lesions. In transitional lesions, immunoreactive myeloperoxidase was predominantly localized to the highly cellular shoulder region. Intracellular immunostaining for myeloperoxidase was clearly present in these regions, which also reacted strongly with an antimacrophage antibody. The Macrophage-rich lesions from hypercholesterolemic rabbits exhibit predominantly cell-associated immunostaining with antibodies that recognize several protein-bound lipid oxidation products (17, 66) . Because phagocytosis is a potent stimulus for H202 generation and myeloperoxidase secretion into the phagolysosome, cell-associated lipid oxidation products might result from aggregated lipoproteins that have been phagocytosed by mononuclear cells (70) . Macrophages are also known to secrete myeloperoxidase extracellularly in response to cellular activation (43) (44) (45) . Atherosclerotic lesions from hypercholesterolemic rabbits exhibit extensive extracellular immunostaining for oxidation-specific epitopes in the necrotic core of advanced lesions, often in association with extracellular lipid deposits (66) . The remarkable similarities in the patterns of immunostaining of myeloperoxidase in human lesions and that of oxidized lipids in rabbit lesions supports the hypothesis that myeloperoxidase is involved in lipoprotein oxidation in vivo.
One important question raised by our observations is the cellular origin of myeloperoxidase. Myeloperoxidase represents up to 5% of neutrophil protein (43, 57, 58) , but this cell type is not thought to play a role in atherogenesis (1, 71) . In agreement with this notion, an antibody specific for neutrophil elastase failed to immunostain atherosclerotic tissue. However, we cannot exclude the possibility that neutrophils are a source of myeloperoxidase because these short-lived cells might be present transiently in diseased artery tissue. Myeloperoxidase is less abundant in monocytes but still represents -1% of total protein (72) . The shoulder region of atherosclerotic lesions is thought to be a locus for monocyte recruitment ( 1, 66, 71 ) and this region exhibited considerable immunoreactivity with the myeloperoxidase antibodies. Myeloperoxidase disappears from monocytes during differentiation in vitro (73), and it is generally believed to be absent from macrophages (43, 57, 58, 74 (43, 57, 58, 75) , from secreted protein that has been recognized and endocytosed via mannose receptors (76), or from enzyme present in phagolysosomes. Indeed, phagocytosis is a potent stimulus for secretion of myeloperoxidase and H202 into the phagolysosome, and this microenviroment is optimized for the oxidative damage of lipids and proteins (43) (44) (45) . It is also possible that macrophages synthesize myeloperoxidase in response to cytokines or other regulatory factors, as has been proposed for 15-lipoxygenase (77) .
By generating products that convert LDL to atherogenic particles (78) , myeloperoxidase may affect early atherogenic events such as migration of monocytes into the intima of the artery wall (9) and accumulation of cholesteryl esters (2) (3) (4) . Stimulated monocytes generate H202 that is used by myeloperoxidase as an oxidative substrate. Because C1-is abundant in plasma, one important product of the myeloperoxidase-H202 system is probably HOCl (42) (43) (44) (45) , which oxidizes unsaturated lipids (37, 38) and reactive protein groups such as thiols, amines, and hemes (39) (40) (41) . Recent studies reveal that HOC1 modifies LDL (47) (48) (49) , increasing its negative charge and forming products that stimulate cholesterol deposition in macrophages (49) . Lipoproteins with similar properties have been isolated from atherosclerotic lesions ( 16, 17) . Myeloperoxidase may also promote lipoprotein oxidation by generating tyrosyl radical (46, 50) , which cross-links L-tyrosine residues in proteins (50, 79) . Dityrosine, a stable product of tyrosine oxidation, accumulates in vitro at plasma concentrations of amino acids and C1- (46, 79) .
The demonstration of the links between myeloperoxidase and oxidative damage to proteins and lipids (36-41, 46, 79) implicates the enzyme in atherogenesis (78) . The detection of the enzyme in diseased human vascular tissue is strong support for the hypothesis that myeloperoxidase, with its ability to promote lipoprotein oxidation by pathways involving HOCl and tyrosyl radical (47) (48) (49) (50) , might be a pivotal agent in the development of atherosclerotic lesions.
